Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 July 2006, Vol. 108, No. 2, pp. 419-425.
Prepublished online as a Blood First Edition Paper on April 11, 2006; DOI 10.1182/blood-2005-10-4149.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-10-4149v1
108/2/419    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cheson, B. D.
Right arrow Articles by Kantarjian, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cheson, B. D.
Right arrow Articles by Kantarjian, H.
Related Collections
Right arrow Neoplasia
Right arrow Clinical Trials and Observations
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

PERSPECTIVES

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

Bruce D. Cheson, Peter L. Greenberg, John M. Bennett, Bob Lowenberg, Pierre W. Wijermans, Stephen D. Nimer, Antonio Pinto, Miloslav Beran, Theo M. de Witte, Richard M. Stone, Moshe Mittelman, Guillermo F. Sanz, Steven D. Gore, Charles A. Schiffer, and Hagop Kantarjian

From the Department of Hematology/Oncology, Georgetown University Hospital, Washington, DC; the Stanford University Cancer Center, CA; the James P. Wilmot Cancer Center at the University of Rochester Medical Center, NY; the Erasmus University Medical Center, Rotterdam, The Netherlands; the Ziekenhuis, Leynburg, The Hague, The Netherlands; the Centro di Riferimento Oncologico, Aviano, Italy; the Memorial Sloan-Kettering Cancer Center, New York, NY; the Department of Leukemia, University of Texas, M. D. Anderson Cancer Center, Houston; the Department of Hematology, Radboud University Nijmegen Medical Centre Central, Nijmegen, The Netherlands; the Dana-Farber Cancer Institute, Boston, MA; the Department of Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv University, Sackler School of Medicine, Tel Aviv, Israel; the Hospital Universitario La Fe, Valencia, Spain; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; the Karmanos Cancer Center, Wayne State University, Detroit, MI; and the Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston.

Abstract

The myelodysplastic syndromes (MDSs) are heterogeneous with respect to clinical characteristics, pathologic features, and cytogenetic abnormalities. This heterogeneity is a challenge for evaluating response to treatment. Therapeutic trials in MDS have used various criteria to assess results, making cross-study comparisons problematic. In 2000, an International Working Group (IWG) proposed standardized response criteria for evaluating clinically significant responses in MDS. These criteria included measures of alteration in the natural history of disease, hematologic improvement, cytogenetic response, and improvement in health-related quality of life. The relevance of the response criteria has now been validated prospectively in MDS clinical trials, and they have gained acceptance in research studies and in clinical practice. Because limitations of the IWG criteria have surfaced, based on practical and reported experience, some modifications were warranted. In this report, we present recommendations for revisions of some of the initial criteria.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
JCOHome page
M. Jadersten, L. Malcovati, I. Dybedal, M. Giovanni Della Porta, R. Invernizzi, S. M. Montgomery, C. Pascutto, A. Porwit, M. Cazzola, and E. Hellstrom-Lindberg
Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome
J. Clin. Oncol., July 20, 2008; 26(21): 3607 - 3613.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. M. Sloand, C. O. Wu, P. Greenberg, N. Young, and J. Barrett
Factors Affecting Response and Survival in Patients With Myelodysplasia Treated With Immunosuppressive Therapy
J. Clin. Oncol., May 20, 2008; 26(15): 2505 - 2511.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. D. Nimer
Myelodysplastic syndromes
Blood, May 15, 2008; 111(10): 4841 - 4851.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. B. Klisovic, W. Stock, S. Cataland, M. I. Klisovic, S. Liu, W. Blum, M. Green, O. Odenike, L. Godley, J. V. Burgt, et al.
A Phase I Biological Study of MG98, an Oligodeoxynucleotide Antisense to DNA Methyltransferase 1, in Patients with High-Risk Myelodysplasia and Acute Myeloid Leukemia
Clin. Cancer Res., April 15, 2008; 14(8): 2444 - 2449.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. Malcovati, M. Cazzola, and U. Germing
In Reply
J. Clin. Oncol., March 1, 2008; 26(7): 1181 - 1182.
[Full Text] [PDF]


Home page
BloodHome page
S. Boehrer, L. Ades, T. Braun, L. Galluzzi, J. Grosjean, C. Fabre, G. Le Roux, C. Gardin, A. Martin, S. de Botton, et al.
Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study
Blood, February 15, 2008; 111(4): 2170 - 2180.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Schmitt, A. Schmitt, M. T. Rojewski, J. Chen, K. Giannopoulos, F. Fei, Y. Yu, M. Gotz, M. Heyduk, G. Ritter, et al.
RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses
Blood, February 1, 2008; 111(3): 1357 - 1365.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Kurzrock, H. M. Kantarjian, M. A. Blascovich, C. Bucher, S. Verstovsek, J. J. Wright, S. R. Pilat, J. E. Cortes, E. H. Estey, F. J. Giles, et al.
Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome
Clin. Cancer Res., January 15, 2008; 14(2): 509 - 514.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Park, S. Grabar, C. Kelaidi, O. Beyne-Rauzy, F. Picard, V. Bardet, V. Coiteux, G. Leroux, P. Lepelley, M.-T. Daniel, et al.
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience
Blood, January 15, 2008; 111(2): 574 - 582.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Raza, J. A. Reeves, E. J. Feldman, G. W. Dewald, J. M. Bennett, H. J. Deeg, L. Dreisbach, C. A. Schiffer, R. M. Stone, P. L. Greenberg, et al.
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q
Blood, January 1, 2008; 111(1): 86 - 93.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
T. Siitonen, T. Timonen, E. Juvonen, V. Terava, A. Kutila, T. Honkanen, M. Mikkola, H. Hallman, M. Kauppila, P. Nylanden, et al.
Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes
Haematologica, August 1, 2007; 92(8): 1119 - 1122.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Fenaux, A. Raza, G. J. Mufti, C. Aul, U. Germing, H. Kantarjian, L. Cripe, R. Kerstens, P. De Porre, and R. Kurzrock
A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome
Blood, May 15, 2007; 109(10): 4158 - 4163.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. Estey
Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients
J. Clin. Oncol., May 10, 2007; 25(14): 1908 - 1915.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Kantarjian, Y. Oki, G. Garcia-Manero, X. Huang, S. O'Brien, J. Cortes, S. Faderl, C. Bueso-Ramos, F. Ravandi, Z. Estrov, et al.
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Blood, January 1, 2007; 109(1): 52 - 57.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Raza, F. Z. Raza, N. Galili, H. M. Kantarjian, Y. Oki, and J.-P. Issa
Low-dose decitabine and high-risk MDS
Blood, December 15, 2006; 108(13): 4291 - 4292.
[Full Text] [PDF]


Home page
BloodHome page
A. Tefferi, G. Barosi, R. A. Mesa, F. Cervantes, H. J. Deeg, J. T. Reilly, S. Verstovsek, B. Dupriez, R. T. Silver, O. Odenike, et al.
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
Blood, September 1, 2006; 108(5): 1497 - 1503.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
C. A. Schiffer
Clinical Issues in the Management of Patients with Myelodysplasia
Hematology, January 1, 2006; 2006(1): 205 - 210.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020